Dynavax Will Not Pursue Narrow Indication For Heplisav After Meeting With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will be collecting additional safety data for approval of its hepatitis B vaccine in adults 18 to 70 years old; the size, duration and cost of the study are yet to be determined.